Eli Lilly Breaks Injection Barrier with New GLP-1 Pill

Eli Lilly's Foundayo addresses a major adoption barrier: patient preference for pills over injections. As GLP-1 drugs transition from injectable to oral forms, the pharmaceutical industry gains manufacturing flexibility and can potentially reach a broader market that was previously reluctant to use needles. This development could resolve supply shortages that plagued the category for years and solidify Lilly's position against competitors like Novo Nordisk.